Verisign
VRSN
$300.32
-1.40%
VeriSign operates the authoritative registry infrastructure for the .com, .net, .name, and .cc generic top-level domains and provides back-end systems for .edu, earning revenue through annual per-domain registration and renewal fees collected from registrars rather than end users. The company functions as a regulated monopoly-like toll booth on internet addressing, with its pricing and operations governed by renewable agreements with the US Department of Commerce and ICANN, a structure that produces exceptionally high margins and predictable cash flows but caps organic growth. The current investor debate centers on the durability of the .com franchise amid modest but steady domain base expansion, periodic six-year registry agreement renewals, and the company's aggressive capital return program funded by debt and free cash flow. Recent quarterly results showing mid-single-digit revenue growth with roughly 50% net margins have reinforced the narrative of VeriSign as a low-beta, bond-proxy-like compounder, while the stock's strong year-to-date advance reflects renewed appetite for defensive quality and pricing-power assets.…
VRSN
Verisign
$300.32
Investment Opinion: Should I buy VRSN Today?
Rating: Hold. VeriSign is a high-quality, monopoly-like registry operator with exceptional 88.5% gross margins and predictable 6% revenue growth, but at $300.32 the stock trades near its 52-week high and offers only 9.0% upside to the $327.40 average analyst target, a modest return for a low-beta defensive name. The consensus 'buy' rating with a mean of 1.8 reflects confidence in cash-flow durability rather than any expectation of acceleration, and the current valuation already prices in steady-state performance.
The supporting evidence is strong: revenue grew 6.03% year-over-year to $434.6 million in Q2 2026, net margin held at 49.8%, and TTM free cash flow of $1.07 billion provides a 4.7% FCF yield. The company returns substantial capital through $201.4 million of Q2 buybacks and a 0.96% dividend yield, while its 45.1% ROA confirms efficient asset utilization despite negative book equity. However, the 27.5x PE sits at a premium to the high-teens to low-20s industry average, and the near-identical trailing and forward multiples imply only a few percent of EPS growth, limiting multiple expansion potential.
The biggest risks that could invalidate the thesis are adverse registry agreement renewal terms, a slowdown in domain growth, and valuation compression toward the historical low of 19.8x. This Hold would upgrade to Buy if the stock pulls back to the $270-$280 support zone (implying ~15% upside to the average target) or if a favorable registry renewal includes pricing flexibility. It would downgrade to Sell if revenue growth decelerates below 4% or if renewal terms impose pricing controls. Relative to its own history and peers, VRSN is fairly valued—neither stretched nor cheap—with the premium justified by its exceptional margins and cash-flow visibility.
Sign up to view all
VRSN 12-Month Price Forecast
VeriSign presents a balanced risk/reward at the current price of $300.32, with the bull case driven by its monopoly-like registry economics and predictable cash flows, and the bear case centered on premium valuation and regulatory renewal risk. The 9.0% upside to the average analyst target is modest for a low-beta name, and the near-identical trailing and forward PE multiples suggest limited earnings acceleration. However, the 4.7% FCF yield and consistent capital returns provide downside support, and the stock's 19.85% one-year return demonstrates its ability to outperform in defensive rotations. I would upgrade to bullish if the stock pulls back to the $270-$280 support zone or if a favorable registry renewal is announced with pricing flexibility; I would downgrade to bearish if revenue growth decelerates below 4% or if renewal terms impose pricing controls.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Verisign's 12-month outlook, with a consensus price target around $336.40 and implied upside of +12.0% versus the current price.
Average Target
$336.40
0 analysts
Implied Upside
+12.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$290 - $380
Analyst target range
Five analysts cover VeriSign with a consensus recommendation of "buy" and a mean rating of 1.8 on a scale where 1 is strong buy, indicating a moderately bullish tilt. The average target price of $327.40 implies roughly 9.0% upside from the current $300.32, a modest but positive expected return consistent with a low-beta defensive name. Consensus EPS estimates of $12.66 for the forward period and revenue estimates of approximately $2.10 billion align with the company's steady mid-single-digit growth trajectory, and the bullish consensus reflects confidence in cash-flow durability rather than any expectation of acceleration.
The target range spans $290 to $355, a spread of about 22% around the average that signals moderate conviction rather than uniform agreement. The high target of $355 (roughly 18% above the current price) likely assumes multiple expansion toward the upper end of the historical PE band or faster domain growth and pricing actions, while the low target of $290 (about 3.4% below current) prices in multiple compression or slower renewal trends. Institutional ratings show a stable pattern: Wedbush and Baird maintain Outperform, Citigroup reiterates Buy, and JP Morgan remains Neutral across multiple updates in 2026, with no recent downgrades or upgrades, suggesting analysts are in a holding pattern awaiting the next registry agreement renewal or domain-base data point. The narrow dispersion and absence of negative actions indicate relatively strong conviction in the steady-state thesis.
Bulls vs Bears: VRSN Investment Factors
The bull case rests on VeriSign's exceptional 88.5% gross margin, 49.8% net margin, and monopoly-like registry model that generates highly predictable 6% revenue growth and $1.07 billion in TTM free cash flow, supported by a consensus buy rating and $327.40 average target. The bear case centers on a premium 27.5x PE that already prices in steady-state performance, a leveraged balance sheet with negative equity, and regulatory renewal risk that could alter the franchise's economics. On balance, the bull evidence is stronger given the company's consistent execution, low beta of 0.692, and market-beating 19.85% one-year return, but the modest 9% analyst upside and near-52-week-high price limit near-term reward. The single most important tension is whether the next registry agreement renewal preserves VeriSign's pricing power and monopoly economics—any adverse terms would undermine the entire investment thesis, while favorable terms would validate the premium multiple.
Bullish
- Monopoly-like registry with 88.5% gross margin: VeriSign operates the authoritative registry for .com and .net under renewable agreements with the US Department of Commerce and ICANN, producing gross margin of 88.5% and operating margin of 67.7% in Q2 2026. The near-zero marginal cost of registry operations and contractual per-domain fees create a toll-booth economics model with exceptional pricing power.
- Steady 6% revenue growth with high visibility: Q2 2026 revenue of $434.6 million grew 6.03% year-over-year from $409.9 million, continuing a consistent 5-6% cadence across six quarters. Subscription-like annual renewal fees and periodic price increases make the top line highly predictable, supporting the defensive cash-flow compounder thesis.
- Strong free cash flow and capital returns: TTM free cash flow of $1.07 billion against a $22.4 billion market cap implies a 4.7% FCF yield, while quarterly operating cash flow of $231.6 million comfortably funds $18.8 million of capex and $73.6 million of dividends. The company repurchased $201.4 million of stock in Q2 2026 alone, enhancing per-share value.
- Analyst consensus buy with 9% upside: Five analysts rate VRSN a consensus 'buy' with a mean rating of 1.8 and an average target price of $327.40, implying roughly 9.0% upside from $300.32. The high target of $355 suggests 18% upside if multiple expansion or faster domain growth materializes.
Bearish
- Premium valuation leaves little room for error: At 27.5x trailing earnings and 13.55x price-to-sales, VRSN trades at a premium to typical software infrastructure peers in the high-teens to low-20s PE range. The 20.4x EV/EBITDA multiple reflects a quality premium that could compress if growth decelerates or registry renewal terms become less favorable.
- Negative equity and weak current ratio: The company carries a negative debt-to-equity ratio of -0.835 and a current ratio of just 0.489, reflecting years of debt-funded buybacks that created an equity deficit. While negative ROE of -38.3% is an artifact of negative book equity, the leveraged capital structure adds financial risk if cash flows ever disappoint.
- Modest growth limits multiple expansion: Revenue growth of 6.03% and near-identical trailing and forward PE multiples of 27.5x and 27.4x imply analysts expect only a few percent of EPS expansion. Without an acceleration catalyst, the stock's upside is largely capped by its earnings growth rate, making the 9% analyst target upside modest.
- Regulatory renewal risk overhangs the franchise: VeriSign's registry agreements with the US Department of Commerce and ICANN are subject to renewal every six years, and any unfavorable terms on pricing or operations could impair the monopoly economics. The absence of recent news or analyst upgrades suggests the market is in a holding pattern awaiting clarity on the next renewal.
VRSN Technical Analysis
VeriSign is in a sustained, orderly uptrend, with the shares up 19.85% over the trailing year and 24.86% year-to-date, comfortably outperforming the S&P 500's 13.13% and 11.45% respective gains. At the current price of $300.32, the stock sits at roughly 94.5% of its 52-week range of $208.86 to $312.48, positioning it near the upper end of its band and signaling persistent accumulation rather than a value dislocation. This proximity to highs implies momentum is intact but leaves limited cushion against mean reversion, particularly given the stock's low 0.692 beta, which suggests moves are driven by company-specific fundamentals rather than broad market swings.
Short-term momentum is positive but decelerating relative to the longer-term trend: the stock is up 2.40% over the past month and 7.26% over three months, both well below the 19.85% one-year gain, indicating a consolidation phase after a strong first half. The 1-month relative strength versus SPY of +3.42% and 3-month relative strength of +4.41% confirm VeriSign continues to outperform even as absolute momentum cools, a healthy divergence that argues for digestion rather than reversal. The 180-day price series shows a sharp June drawdown to $247.22 followed by a methodical recovery through $300, with the recent pullback from the $308.18 September high to $300.32 representing a modest 2.5% retracement rather than a trend break.
Key technical resistance sits at the 52-week high of $312.48, roughly 4% above the current price; a decisive breakout would confirm the uptrend's continuation and likely invite momentum-driven buying. Support is anchored at the 52-week low of $208.86, but more relevant near-term support lies in the $280-$285 zone where the stock consolidated in late September and early October. With a beta of 0.692, VeriSign is roughly 31% less volatile than the market, meaning position sizing can be larger for equivalent risk contribution, though the stock's max drawdown of -26.22% over the period shows it is not immune to sharp corrections when sentiment shifts.
Beta
0.69
0.69x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$209-$312
Price range past year
Annual Return
+19.8%
Cumulative gain past year
| Period | VRSN Return | S&P 500 |
|---|---|---|
| 1m | +2.4% | -1.5% |
| 3m | +7.3% | +2.8% |
| 6m | +11.6% | +6.8% |
| 1y | +19.8% | +12.2% |
| ytd | +24.9% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRSN Fundamental Analysis
Revenue is growing steadily but modestly: Q2 2026 revenue of $434.6 million rose 6.03% year-over-year from $409.9 million, continuing a consistent cadence of roughly 5-6% growth across the trailing six quarters ($402.3M, $409.9M, $419.1M, $425.3M, $428.9M, $434.6M). This sequential progression reflects the contractual, subscription-like nature of registry fees, where growth is driven by net domain additions and periodic price increases rather than cyclical demand. The trajectory implies a highly predictable top line with limited acceleration potential, reinforcing the investment case as a defensive cash-flow compounder rather than a growth story.
Profitability is exceptional and stable: Q2 2026 net income of $216.5 million on $434.6 million of revenue produced a 49.8% net margin, while gross margin of 88.5% and operating margin of 67.7% reflect the near-zero marginal cost of registry operations. Margins have been remarkably consistent, with gross margin ranging narrowly between 88.0% and 88.5% over the past six quarters and net margin holding near 50%, demonstrating pricing power and operating leverage inherent in the monopoly-like registry model. The company is firmly profitable with no trajectory concerns, and its margin profile is among the highest in the software infrastructure industry.
Balance sheet and cash flow metrics require careful interpretation: free cash flow TTM of $1.07 billion against a $22.4 billion market cap implies a roughly 4.7% FCF yield, and quarterly operating cash flow of $231.6 million comfortably funds $18.8 million of capex and $73.6 million of dividends. However, the company carries substantial leverage, evidenced by a negative debt-to-equity ratio of -0.835 and a current ratio of just 0.489, reflecting an equity deficit from years of buybacks funded by debt; Q2 2026 alone saw $546.4 million of debt repayment alongside $201.4 million of stock repurchases. The negative ROE of -38.3% is an artifact of negative book equity rather than operational weakness, as confirmed by a strong 45.1% ROA, meaning the company generates ample cash internally but deliberately operates with a leveraged, shareholder-return-focused capital structure.
Quarterly Revenue
$434600000.0B
2026-06
Revenue YoY Growth
+6.0%
YoY Comparison
Gross Margin
88.5%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRSN Overvalued?
Because VeriSign is solidly profitable with trailing net income of roughly $850 million annualized, the PE ratio is the appropriate primary metric; the stock trades at 27.5x trailing earnings and 27.4x forward earnings, an unusually narrow gap that implies the market expects only modest earnings growth ahead. The near-identical trailing and forward multiples suggest analysts anticipate EPS expansion of just a few percent, consistent with the company's low-single-digit revenue growth and mature capital-return model rather than any inflection in operating performance.
Against the broader software infrastructure sector, VeriSign's 27.5x PE sits at a premium to typical industry averages in the high-teens to low-20s, while its 13.55x price-to-sales and 16.87x EV-to-sales ratios are elevated in absolute terms but must be contextualized against an 88.2% gross margin and 49.8% net margin that are far above sector norms. The 20.4x EV/EBITDA multiple similarly reflects the quality premium investors assign to a regulated, subscription-revenue monopoly with near-perfect revenue visibility. The premium is defensible on profitability and cash-flow durability grounds, though it leaves little room for disappointment on domain growth or registry agreement renewal terms.
Historically, VeriSign's PE has ranged from roughly 19.8x (Q4 2023) to 38.9x (Q1 2022), with the current 27.5x sitting near the middle of that band and well below the 30-33x levels seen through much of 2025. The price-to-sales ratio of 13.55x compares favorably to historical readings that exceeded 50x on a different share-count basis but has compressed as earnings have grown into the multiple. The current valuation is neither stretched nor cheap relative to the stock's own history, suggesting the market is pricing a fair, steady-state outcome rather than either euphoria or distress.
PE
27.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 20x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.4x
Enterprise Value Multiple
Investment Risk Disclosure
VeriSign's financial risks stem from its deliberately leveraged capital structure, evidenced by a negative debt-to-equity ratio of -0.835 and a current ratio of just 0.489, the result of years of debt-funded buybacks that created an equity deficit. While TTM free cash flow of $1.07 billion and quarterly operating cash flow of $231.6 million comfortably cover $18.8 million of capex and $73.6 million of dividends, the company repaid $546.4 million of debt in Q2 2026 alongside $201.4 million of repurchases, leaving limited liquidity cushion. Revenue concentration in .com and .net registry fees means any slowdown in net domain additions or renewal rates would directly pressure the top line, and the modest 6.03% growth rate offers little buffer against cost inflation or interest expense of $19.2 million per quarter. The negative ROE of -38.3% is an accounting artifact of negative book equity rather than operational weakness, as confirmed by a 45.1% ROA, but it complicates traditional leverage analysis and could deter some institutional investors.
Market and competitive risks center on valuation compression: at 27.5x trailing earnings and 13.55x price-to-sales, VRSN trades at a premium to software infrastructure peers in the high-teens to low-20s PE range, leaving little room for disappointment. The stock's low beta of 0.692 means it is less sensitive to broad market swings, but its 19.85% one-year return and 24.86% year-to-date gain have been driven by defensive rotation into quality assets—a reversal of that sentiment could trigger multiple compression toward the historical low of 19.8x seen in Q4 2023. Regulatory risk is ever-present given the six-year renewal cycle for registry agreements with the US Department of Commerce and ICANN, and any push for pricing controls or operational changes could impair the monopoly economics. Competitive threats from alternative top-level domains and changing internet addressing standards are long-term risks, though the .com franchise's entrenched position provides substantial moat.
A worst-case scenario would involve a combination of adverse registry renewal terms, a slowdown in domain growth, and a broader de-rating of defensive quality stocks. In this scenario, the stock could retrace to its 52-week low of $208.86, representing a 30.5% decline from the current $300.32, or to the analyst low target of $290, a 3.4% decline. A more severe outcome, such as a regulatory mandate for lower pricing, could push the stock below the 52-week low toward the historical PE trough of 19.8x, implying a price near $216 based on forward EPS of $12.66, a 28% downside. The max drawdown of -26.22% over the past 180 days, including the June drop to $247.22, illustrates that sharp corrections are possible even for low-beta names when sentiment shifts.
FAQ
The most severe risk is regulatory: VeriSign's registry agreements with the US Department of Commerce and ICANN are subject to six-year renewals, and adverse terms on pricing or operations could impair the monopoly economics. Financial risk stems from the leveraged balance sheet, with a negative debt-to-equity ratio of -0.835 and a current ratio of 0.489, the result of debt-funded buybacks. Valuation risk is significant given the 27.5x PE premium; compression toward the historical low of 19.8x would imply a price near $250, a 17% decline. Competitive risk from alternative top-level domains and changing internet standards is a long-term threat, though the .com franchise's entrenched position provides a substantial moat. Ranked by severity: regulatory renewal, valuation compression, financial leverage, and competitive disruption.
The 12-month forecast has three scenarios: a base case (55% probability) targeting $315-$330, aligned with the $327.40 analyst average, assuming steady 5-6% revenue growth and a smooth registry renewal; a bull case (25% probability) targeting $340-$355, driven by favorable renewal terms and multiple expansion; and a bear case (20% probability) targeting $209-$290, reflecting adverse renewal terms or growth deceleration. The base case is most likely, as it assumes VeriSign continues its consistent execution with stable margins and capital returns. The key assumption is that the next registry agreement renewal preserves current pricing flexibility and operational terms, allowing the company to maintain its 6% revenue cadence and 50% net margin.
VRSN appears fairly valued at 27.5x trailing earnings, sitting near the middle of its historical PE range of 19.8x to 38.9x. The 13.55x price-to-sales and 20.4x EV/EBITDA multiples are elevated in absolute terms but justified by 88.5% gross margins and 49.8% net margins that far exceed software infrastructure peers. The near-identical trailing and forward PE multiples of 27.5x and 27.4x imply the market expects only a few percent of EPS growth, consistent with the company's mature 6% revenue trajectory. Compared to peers trading in the high-teens to low-20s PE range, VRSN carries a quality premium that is defensible but leaves little room for disappointment. The market is pricing a steady-state outcome, not euphoria or distress.
VRSN is a good buy for defensive investors seeking stable cash flows, but the current price of $300.32 offers only 9.0% upside to the $327.40 average analyst target, which is modest for a low-beta name. The company's 88.5% gross margin and 49.8% net margin provide exceptional profitability, and the 4.7% FCF yield supports capital returns. However, the 27.5x PE is at a premium to peers, and the stock sits near its 52-week high of $312.48, leaving limited margin of safety. The biggest downside risk is a 30.5% decline to the 52-week low of $208.86 if registry renewal terms disappoint. For long-term investors comfortable with modest upside and low volatility, VRSN is a reasonable hold, but new buyers may find better entry points near the $270-$280 support zone.
VRSN is best suited for long-term investment given its low beta of 0.692, predictable subscription-like revenue, and consistent capital returns through buybacks and dividends. The stock's 19.85% one-year return and 24.86% year-to-date gain demonstrate its ability to compound steadily, but short-term trading is less attractive due to its low volatility and modest 2.40% one-month gain. The 0.96% dividend yield and $201.4 million quarterly buyback program provide income and per-share value enhancement for patient holders. Earnings visibility is high due to contractual registry fees, but the six-year renewal cycle introduces periodic event risk. A suggested minimum holding period is 3-5 years to capture a full renewal cycle and the compounding of free cash flow.